| Patent application number | Description | Published |
|---|
| 20080273471 | Terminal Device, System And Method For Measuring Traffic Based On User Services - A terminal device includes a service type distinguishing module and a traffic measuring module. The service type distinguishing module is adapted to distinguish types of services accessed by the terminal device; the traffic measuring module is adapted to measure the traffic of each service type according to the service types distinguished by the service type distinguishing module. The present disclosure also discloses a system and method for measuring traffic based on user services. With the technical scheme of the disclosure, traffic of different service types can be measured respectively on a terminal device, so that the charging system is able to apply different charging policies to different service types. | 11-06-2008 |
| 20080304830 | PASSIVE OPTICAL NETWORK, EQUIPMENT AND METHOD FOR SUPPORTING MULTICAST SERVICE - A Wavelength Division Multiplexed Passive Optical Network (WDM-PON), an Optical Line Terminal, an Optical Network Unit, a multiplexer/demultiplexer, and a method for realizing multicast service in the WDM-PON are disclosed. The WDM-PON and the method for realizing multicast service according to the present invention can transmit multicast service to be multicasted or broadcasted using a single wavelength, and thus the bandwidth resource of the system can be effectively saved and complexity of the system can be reduced. | 12-11-2008 |
| 20090175303 | LIGHT SOURCE MODE ALIGNMENT DEVICE AND METHOD, PASSIVE OPTICAL NETWORK SYSTEM - A light source mode alignment device and method and a passive optical network system are provided. The device includes a laser and a temperature control unit connected to each other and further includes a signal processing unit. The laser converts an incident light into a current signal. The current signal is amplified and converted into a voltage signal via a transimpedance amplifier. Together with a modulation signal generated by the signal processing unit, the voltage signal adjusts a bias voltage of the temperature control unit. | 07-09-2009 |
| 20100273537 | SIDE GROUNDED STRUCTURE FOR COMBINED BATTERY LID OF MOBILE COMMUNICATION TERMINAL - A side grounded structure for combined battery lid of mobile communication terminal is provided, which comprises a metallic battery lid, and there is a plastic layer set in the metallic battery lid, and a spring contact slice is set between the metallic battery lid and the plastic layer, the spring contact slice is connected to the metallic battery lid and has a curve contact section used to connect the grounded down-lead of the circuit board. By adopting the combined structure of battery lid and equipping the spring contact slice in the battery lid, the side grounded structure for combined battery lid of mobile communication terminal in present invention conveniently realizes the ground contact, assures the efficiency of the contact, enables the convenient production, improves the product yield and reduces consumption and cost in manufacture. | 10-28-2010 |
| 20120069840 | METHOD AND SYSTEM FOR CIRCUIT-SWITCHED CORE NETWORK EVOLUTION, AND NETWORK DEVICE - Embodiments of the present invention disclose a method and a system for CS core network evolution, and a network device. The evolution method includes: EMSC connects with an IMS network and serves as a TAS in the IMS network to provide a voice service for a user in the IMS network, where the EMSC is obtained by upgrading a Mobile Switching Center Server in a CS core network and possesses functions of the TAS in the IMS network; and performing, by the EMSC, service processing on a service request for an existing service, and sending a service request for a new service to a corresponding application server in the IMS network for processing, wherein the service request for an existing service and the service request for a new service are initiated by a CS user who has subscribed to a new service. | 03-22-2012 |
| Patent application number | Description | Published |
|---|
| 20080255136 | PYRROLIDONES WITH ANTI-HIV ACTIVITY - The present invention relates to inhibition of viruses, e.g., HIV using pyrrolidones and compounds related to pyrrolidones. The invention further relates to methods for identifying and using agents, including small molecule chemical compositions that inhibit HIV in a cell; as well as to methods of prophylaxis, and therapy related to HIV infection and related disease states such as AIDS. | 10-16-2008 |
| 20090131400 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS - The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction. | 05-21-2009 |
| 20090192121 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS - Novel bisamidate phosphonate prodrugs of FBPase inhibitors of the Formula IA: | 07-30-2009 |
| 20110135668 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-1R), and/or insulin receptor (InsR) or a combination thereof. | 06-09-2011 |
| 20110172139 | PEPTIDES WHOSE UPTAKE BY CELLS IS CONTROLLABLE - A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however, upon extracellular cleavage of X, the B-C portion is taken up, delivering the cargo to targeted cells. Cargo may be, for example, a contrast agent for diagnostic imaging, a chemotherapeutic drug, or a radiation-sensitizer for therapy. Cleavage of X allows separation of A from B, unmasking the normal ability of the basic amino acids in B to drag cargo C into cells near the cleavage event. X is cleaved extracellularly, preferably under physiological conditions. D-amino acids are preferred for the A and B portions, to minimize immunogenicity and nonspecific cleavage by background peptidases or proteases. | 07-14-2011 |
| 20110190259 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof. | 08-04-2011 |
| 20110190264 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS - The invention relates to triazine and pyrimidine derivatives having Formula (1) or (2), and methods for using such compounds. For example, the compounds of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-IR), and/or insulin receptor (InsR) or a combination thereof. | 08-04-2011 |
| 20110257154 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS - The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof. | 10-20-2011 |
| 20120134922 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE - Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A—X—B—C)n—M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier. | 05-31-2012 |
| 20120134931 | PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE - Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A-X-B-C)-M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier. | 05-31-2012 |
| 20120251445 | PEPTIDES WHOSE UPTAKE BY CELLS IS CONTROLLABLE - A generic structure for the peptides of the present invention includes A-X-B-C, where C is a cargo moiety, the B portion includes basic amino acids, X is a cleavable linker sequence, and the A portion includes acidic amino acids. The intact structure is not significantly taken up by cells; however, upon extracellular cleavage of X, the B-C portion is taken up, delivering the cargo to targeted cells. Cargo may be, for example, a contrast agent for diagnostic imaging, a chemotherapeutic drug, or a radiation-sensitizer for therapy. Cleavage of X allows separation of A from B, unmasking the normal ability of the basic amino acids in B to drag cargo C into cells near the cleavage event. X is cleaved extracellularly, preferably under physiological conditions. D-amino acids are preferred for the A and B portions, to minimize immunogenicity and nonspecific cleavage by background peptidases or proteases. | 10-04-2012 |
